Nutrition & Celiac Disease

Nutrition support in 2027 emphasizes early enteral feeding in critical illness, ESPEN-aligned protein targets, and structured home parenteral nutrition programs with teduglutide for intestinal failure. Celiac disease pharmacotherapy is finally moving beyond the gluten-free diet, with the transglutaminase 2 inhibitor ZED1227 demonstrating mucosal protection in phase 2 and latiglutenase, IMGX003, and AMG 714 (anti-IL-15) advancing through trials. Sessions cover non-responsive and refractory celiac disease, enteropathy-associated T-cell lymphoma surveillance, micronutrient deficiencies after bariatric surgery, and the metabolic management of obesity with GLP-1 and dual incretin agonists.